United States · FDA National Drug Code directory
Xolair PFS
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 50242-214_48785e56-4828-4f55-88e1-eca2cb88299d
- Product NDC
- 50242-214
- Form
- INJECTION, SOLUTION
- Composition / generic term
- omalizumab
- Labeler
- Genentech, Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20180928
- Source listing expiry
- 20271231
Source-listed ingredients
- OMALIZUMAB — 75 mg/.5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 SYRINGE, GLASS in 1 CARTON (50242-214-03) / .5 mL in 1 SYRINGE, GLASS · 50242-214-03
- 1 SYRINGE, GLASS in 1 CARTON (50242-214-55) / .5 mL in 1 SYRINGE, GLASS · 50242-214-55
- 1 SYRINGE, GLASS in 1 CARTON (50242-214-83) / .5 mL in 1 SYRINGE, GLASS · 50242-214-83
- 1 SYRINGE, GLASS in 1 CARTON (50242-214-99) / .5 mL in 1 SYRINGE, GLASS · 50242-214-99
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →